NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. Ten of our biosimilar products are being co-developed in collaboration with Serum Institute of India. NeuClone is also developing an additional range of biosimilars independently.
The development stage of eight products with Serum Institute are outlined below.
ORIGINATOR
Herceptin®
Trastuzumab
Stelara®
Ustekinumab
Prolia®/XGEVA®
Denosumab
Synagis®
Palivizumab
Perjeta®
Pertuzumab
Opdivo®
Nivolumab
Keytruda®
Pembrolizumab
Humira®
Adalimumab
EARLY PRECLINICAL
LATE PRECLINICAL
PROCESS SCALE-UP
PHASE I
PHASE III
12 other products in development.
Herceptin
Trastuzumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2018
Stelara
Ustekinumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2019
Prolia/XGEVA
Denosumab
Early Preclinical
Late Preclinical
Process Scale-up
Synagis
Palivizumab
Early Preclinical
Late Preclinical
Process Scale-up
Perjeta
Pertuzumab
Early Preclinical
Late Preclinical
Process Scale-up
Opdivo
Nivolumab
Early Preclinical
Late Preclinical
Process Scale-up
Keytruda
Pembrolizumab
Early Preclinical
Late Preclinical
Process Scale-up
Humira
Adalimumab
Early Preclinical
Late Preclinical
